Today we kicked off IBM Think 2024 in Boston with Partner Plus Day, a full day dedicated to our partners who are driving client innovation, business growth and scaling the adoption of transformative technology such as generative AI. It is also the perfect opportunity to reflect on the progress and success of the IBM Ecosystem, more than a year after we introduced Partner Plus, the program that embodies our new era of partner-first collaboration.
Machine learning (ML) has become a critical component of many organizations’ digital transformation strategy. From predicting customer behavior to optimizing business processes, ML algorithms are increasingly being used to make decisions that impact business outcomes.
In today’s digital world, organizations are continuously developing, enhancing, upgrading and modernizing Java applications as part of their hybrid cloud strategy. While these are common development activities, they are often wrought with challenges, especially when working with complex enterprise applications that are monolithic, poorly documented or laden with technical debt.
The physics of atoms and the technology behind treating disease might sound like disparate fields. However, in the past few decades, advances in artificial intelligence, sensing, simulation and more have driven enormous impacts within the biotech industry.
A new study by the IBM Institute for Business Value found that surveyed CEOs are facing workforce, culture and governance challenges as they act quickly to implement and scale generative AI across their organizations.
